Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm (1)
Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019 Capital Markets and Public M&A

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Related

Vinge advises Impilo on the establishment of a continuation fund

 Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.
November 15, 2024

Vinge advises Österlens Kraft economic association in connection with the sale of all shares in Österlens Kraft Fjärrvärme AB to Adven Sverige AB

 Österlens Kraft Fjärrvärme AB produces, distributes and sells district heating to the company's customers in Simrishamn.
November 14, 2024

Vinge advises Abacus Bidco Oy (which is the parent company of Accountor Software recently acquired by KKR) in the acquisition of certain subsidiaries and assets of 24SevenOffice Group AB (“24SevenOffice”)  

 24SevenOffice is a listed company (First North Stockholm) that provides modular software for accounting, ERP and business services that automate processes using AI.
November 13, 2024